Management Quality -- 7.5/10
CHD scores a 7.5 on management quality. The beat-and-raise cadence through 2024 was exemplary --
CHD beat quarterly EPS guidance by $0.01-$0.12 every single quarter. The Farrell-to-Dierker CEO
transition was textbook: orderly, internal, no strategic discontinuity. Capital allocation is
disciplined (1.5x leverage, bolt-on M&A only), and the team showed operational agility through
the 2025 tariff/destocking storm with industry-leading tariff mitigation. Deductions come from the
Q1 2025 organic miss (-1.2% vs. 0-2% guide), the VMS acquisition ultimately requiring years of
impairments before divestiture, and FY2025 organic growth of just 0.7% -- well below the evergreen
4% target.
Weight: 20%
CEO
Rick Dierker (since Jan 2025)
Internal promotion from CFO | Matt Farrell retired end of 2024
Promise Delivery
10/12 MET or BEAT, 1 Miss
Conservative guide-and-beat pattern | Q1 2025 the sole miss
Leverage
1.5x Net Debt/EBITDA
Disciplined balance sheet | Bolt-on M&A only (Touchland, Hero, TheraBreath)
Evergreen Algorithm
4% Organic / 8% EPS Growth
Raised from 3% organic at CAGNY 2025 | Gross margin target 50-75 bps/yr
Leadership team
Rick Dierker -- President & CEO (since Jan 2025)
Former CFO (2015-2024), promoted to President & COO in late 2024, then CEO in
January 2025. Deep knowledge of the evergreen algorithm. Immediately faced a stress
test (tariffs + consumer softness + retailer destocking) and navigated it decisively
with portfolio pruning, tariff mitigation, and transparent communication. Described
CHD tariff response as "not just industry-leading... it is just leading."
Matt Farrell -- Former Chairman & CEO (2016-2024)
Oversaw nearly a decade of consistent compounding under the ~3% organic growth
algorithm. Built the acquisition playbook (Hero Cosmetics, TheraBreath, Zicam)
that defined CHD as a bolt-on acquirer of niche #1/#2 brands. Retired at end of
2024 in an orderly, well-telegraphed transition -- a hallmark of strong management
culture.
Lee McChesney -- CFO (2025+)
New CFO under Dierker, previously at CHD in FP&A leadership. Internal
appointment, continuing the pattern of promoting from within. Early tenure --
limited independent track record but benefits from institutional continuity
and deep familiarity with the evergreen model and financial discipline.
The evergreen model (long-term algorithm)
| Metric | Evergreen Target | Recent Delivery |
|---|---|---|
| Organic Sales Growth | ~4% (raised from ~3%) | FY2024: 4.6% | FY2025: 0.7% (tariff/destocking headwinds) |
| Gross Margin Expansion | 50-75 bps annually (raised from 25-50 bps) | FY2024: +100-110 bps | FY2025: ~+100 bps -- consistently exceeded |
| Operating Margin Expansion | 25 bps annually | On track |
| EPS Growth | ~8% | FY2024: $3.44 adj. EPS (beat initial guide of $3.42-$3.45) |
The evergreen algorithm has been a reliable framework for nearly a decade. Dierker raised the
organic growth target from ~3% to ~4% and the gross margin expansion target from 25-50 bps to
50-75 bps at the 2025 Analyst Day, signaling confidence in the streamlined portfolio.
Promise tracking (12 promises)
| # | Promise | When | Target | Actual Result | Verdict |
|---|---|---|---|---|---|
| 1 | FY2024 organic sales growth 4-5% | Q1 2024 | 4-5% organic growth | 4.6% -- delivered within/above range | MET |
| 2 | FY2024 adjusted EPS $3.42-$3.45 | Q1-Q3 2024 | $3.42-$3.45 adj. EPS | $3.44 -- beat initial guidance | BEAT |
| 3 | Q2 2024: ~4% organic, ~$0.83 EPS | Q1 2024 | 4% org / $0.83 EPS | 4.7% org / $0.93 EPS -- meaningful upside on both | BEAT |
| 4 | Q3 2024: ~3% organic, ~$0.67 EPS | Q2 2024 | 3% org / $0.67 EPS | 4.3% org / $0.79 EPS -- +130bps org, +$0.12 EPS | BEAT |
| 5 | Q4 2024: ~3-4% organic, ~$0.76 EPS | Q3 2024 | ~$0.76 EPS | 4.2% org / $0.77 EPS | MET |
| 6 | FY2025 organic sales 0-2% | Q4 2024 | 0-2% organic growth | 0.7% -- within range, though at low end | MET |
| 7 | Q1 2025: low end of 0-2% | CAGNY Feb 2025 | Low end of 0-2% | -1.2% -- retailer destocking 300bps drag; worse than expected | MISSED |
| 8 | Q2 2025: -2% to flat, ~$0.85 EPS | Q1 2025 | -2% to 0% / $0.85 | 0.1% org / $0.94 EPS -- exceeded top end on both | BEAT |
| 9 | Q3 2025: 1-2% organic, ~$0.72 EPS | Q2 2025 | 1-2% / $0.72 EPS | 3.4% org / $0.81 EPS -- strong rebound, +140bps, +$0.09 | BEAT |
| 10 | Gross margin expansion annually | Evergreen | 25-50 bps/yr (50-75 bps 2025+) | 2024: +100-110 bps; 2025: ~+100 bps -- consistently exceeded | BEAT |
| 11 | Portfolio pruning: divest VMS, exit Flawless & Showerheads | Q1-Q2 2025 | Execute by end of 2025 | VMS divested, Flawless shut down, Showerheads exited | DELIVERED |
| 12 | Touchland acquisition | Q2 2025 | Close and integrate | Closed Q2 2025; founder retained; accretive to gross margin | DELIVERED |
12 promises tracked. 10 MET or BEAT (quarterly EPS beats, annual guidance, margin expansion,
portfolio pruning, Touchland M&A), 1 SLIGHT BEAT (Q4 2024), 1 MISSED (Q1 2025 organic at
-1.2% vs. low end of 0-2% guide due to retailer destocking). Management has a strong pattern
of setting conservative guidance and beating it.
Source: Earnings call transcripts Q2 2024 through Q4 2025 Analyst Day, Daloopa.
Qualitative strengths
Consistent Beat-and-Raise Cadence
Throughout 2024, CHD beat quarterly EPS guidance by $0.01-$0.12 every single quarter.
This is the hallmark of a management team that sandbaqs conservatively and delivers.
Volume-driven organic growth (not just pricing) demonstrates real brand health.
Evergreen Algorithm Integrity
The ~3% (now 4%) organic growth / 8% EPS growth algorithm has been remarkably consistent
over nearly a decade. FY2024 organic growth of 4.6% exceeded the algorithm. Even in the
difficult 2025, management was transparent about headwinds and kept full-year organic
within the lowered 0-2% guide.
Decisive Portfolio Management
The 2025 decision to divest underperforming VMS, shut down Flawless, and exit Showerheads
was bold and well-executed. Dierker stated: "There is a lot of momentum because of the
portfolio changes we were able to make in 2025." Removed margin drags and simplified
the portfolio.
Industry-Leading Tariff Mitigation
Dierker described the tariff response as "not just industry-leading... it is just leading."
CHD reshored production, adjusted sourcing rapidly, and managed to hold margins through
a very volatile tariff environment in 2025. Speaks to operational agility and supply
chain flexibility.
Smooth CEO Transition
The Farrell-to-Dierker handoff was textbook: long internal tenure, overlapping roles,
no strategic discontinuity. Dierker had been CFO since 2015 and understands every lever
of the business. His first year was a stress test (tariffs + consumer softness) and he
passed it.
Capital Allocation Discipline
Strong balance sheet at 1.5x leverage. Bolt-on M&A (Touchland, Hero, TheraBreath) fits
the model well -- acquiring niche #1/#2 brands and scaling them via CHD distribution.
No dilutive empire-building. Innovation pipeline includes Hero Cosmetics and TheraBreath
growing double digits. Online sales reached ~23% of global.
Red flags assessment
| Red Flag | Status | Detail |
|---|---|---|
| CEO turnover / forced departure | NO | Orderly retirement and internal succession. Textbook transition. |
| CFO turnover | PARTIAL | Dierker moved from CFO to CEO; new CFO (McChesney) appointed -- internal, no disruption. |
| Missed guidance repeatedly | NO | 1 miss out of 12 tracked promises (Q1 2025). Otherwise pristine beat-and-raise record. |
| Aggressive accounting | NO | Non-GAAP adjustments clearly disclosed (Hero restricted stock, ERP costs, tariff ruling). Reasonable. |
| Excessive M&A / leverage | NO | 1.5x leverage; bolt-on M&A only; no mega-deals or empire-building. |
| Insider selling | NO | No unusual patterns noted in transcripts. |
| Board governance concerns | NO | None identified. |
| Evasive on Q&A | NO | Both Farrell and Dierker are direct, detailed, and forthcoming on calls. Confident without being dismissive. |
| Restructuring / impairments | PARTIAL | VMS tradename impairments and business exits in 2024-2025. However, these were decisive portfolio actions, not serial restructuring. |
| Compensation misalignment | NO | No concerns raised in transcripts. |
No major red flags. Two partial flags: (1) CFO turnover is mechanical -- Dierker moved to CEO,
McChesney (internal) replaced him as CFO; and (2) VMS tradename impairments were decisive portfolio
cleanup, not serial restructuring. Neither rises to a serious governance or credibility concern.
Concerns and deductions (why not 8 or higher)
Q1 2025 Guidance Miss
The -1.2% organic in Q1 2025 (vs. low end of 0-2% guide) was a genuine miss. While
management attributed it to retailer destocking (~300bps drag) and was transparent, it
broke an otherwise pristine consecutive-beat streak. The recovery in Q2-Q3 was strong,
but the miss is a data point.
VMS Acquisition -- Strategic Misstep
The Vitamins/Minerals/Supplements business (Vitafusion, L'il Critters) required
multiple tradename impairments before the eventual divestiture. The original acquisition
thesis did not fully play out. Management deserves credit for eventually cutting the
cord, but this was a multi-year drag on returns.
FY2025 Below Evergreen Target
Full-year organic of only 0.7% was well below the evergreen 4% target and even below
the lowered 0-2% initial guide (which was later narrowed). While external factors
(tariffs, consumer softness) were real, this is the first time in years the algorithm
meaningfully underdelivered.
New CEO -- Limited Track Record
Dierker has the right background and pedigree (decade as CFO), but has only one year of
track record in the top seat -- and it was a difficult year. The guidance range widening
in 2025 (0-2% was notably wide) is a minor concern about guide-setting discipline in
volatile environments.
Score rationale
7.5/10. CHD management rates well above average. The beat-and-raise cadence
through 2024 was exemplary, the CEO transition was orderly, capital allocation is disciplined
(1.5x leverage, bolt-on M&A only), and the team showed operational agility through the
2025 tariff/destocking storm. The evergreen algorithm has been a reliable framework for
nearly a decade.
Why not 8+: (1) The Q1 2025 miss broke an otherwise pristine track record; (2) the VMS acquisition was a strategic misstep that required years of impairments before divestiture; and (3) FY2025 organic growth of 0.7% was meaningfully below the evergreen 4% target, even accounting for external headwinds. These are real blemishes on an otherwise strong management team.
What would move this to 8+: If 2026 delivers closer to the 3-4% organic / 8% EPS growth algorithm, demonstrating that the portfolio pruning and tariff mitigation have put CHD back on the evergreen track. One more year of consistent delivery under Dierker would build the confidence needed for a higher score.
Why not 8+: (1) The Q1 2025 miss broke an otherwise pristine track record; (2) the VMS acquisition was a strategic misstep that required years of impairments before divestiture; and (3) FY2025 organic growth of 0.7% was meaningfully below the evergreen 4% target, even accounting for external headwinds. These are real blemishes on an otherwise strong management team.
What would move this to 8+: If 2026 delivers closer to the 3-4% organic / 8% EPS growth algorithm, demonstrating that the portfolio pruning and tariff mitigation have put CHD back on the evergreen track. One more year of consistent delivery under Dierker would build the confidence needed for a higher score.
Data sourced from Daloopa. Analysis based on 6 earnings transcripts (Q2 2024 through Q4 2025 Analyst Day).